Modulating effect of Cu(II) complexes with enamine and tetrazole derivatives on CYP2C and CYP3A and their cytotoxic and antiproliferative properties in HepG2 spheroids

CYP2C and CYP3A cytochromes are induced by a variety of compounds and affect the pharmacokinetics and pharmacodynamics of a large number of drugs. Currently, the possibility of using copper coordination compounds in antitumor therapy is being actively studied. Evaluation of potential interactions between new molecules and P450 cytochromes is necessary at an early stage of drug design.
The aim. To study the modulating effect of Cu(II) complexes with enamine and tetrazole derivatives on CYP2C9, CYP2C19 and CYP3A4 and their cytotoxic and antiproliferative properties on normal human lung fibroblasts MRC-5 and a 3D model of hepatocellular carcinoma HepG2.
Materials and methods. Cytotoxic and antiproliferative activities of copper(II) complexes – [CuL2] (1), [Cu2(bipy)2(PT)4] (2), [Cu2(phen)2(PT)4] (3), {[Cu(phen)(MT)2]∙H2O}n (4) (L – anion of 2-anilinomethylidene-5,5-dimethylcyclohexane-1,3-dione; PT – 5-phenyltetrazolate anion; MT – 5-methyltetrazolate anion; bipy – 2,2’-bipyridine; phen – 1,10-phenanthroline) – were examined in 2D and 3D models using fluorescence-based phenotypic screening. The modulating effect on CYP2C9, CYP2C19 and CYP3A4 was studied using fluorescence-based targeted screening. The results of CYP3A4 expression were confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR).
Results. Complex (1) increases the CYP3A4 expression and does not affect CYP2C9 and CYP2C19 expression. Complex (2) has no modulating effect on CYP2C and CYP3A. Complexes with 1,10-phenatrolin (3) and (4) induce CYP3A4, inhibit CYP2C9 and do not affect CYP2C19 expression. All compounds have a dose-dependent cytotoxic effect on HepG2 and MRC-5: the compound with 5-methyltetrazolate anion (4) has the same effect on cell lines, compounds with 5-phenyltetrazolate anion (2) and (3) have selective effect. Complexes with 1,10-phenatrolin are effective on both 2D and 3D models.
Conclusion. The [Cu2(phen)2(FT)4] complex (3) can be used as a basis for creating an antitumor compound, but further modification of the structure is required to increase the selectivity to tumor cells.

1. Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2022; 161: 108-118. https://doi.org/10.1016/j.ejca.2021.11.023

2. Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: The present and the future. World J Hepatol. 2017; 9(21): 907-920. https://doi.org/10.4254/wjh.v9.i21.907

3. Tsvetkova D, Ivanova S. Application of approved cisplatin derivatives in combination therapy against different cancer diseases. Molecules. 2022; 27(8): 2466. https://doi.org/10.3390/molecules27082466

4. Ndagi U, Mhlongo N, Soliman ME. Metal complexes in cancer therapy - An update from drug design perspective. Drug Des Devel Ther. 2017; 11: 599-616. https://doi.org/10.2147/DDDT.S119488

5. Hordyjewska A, Popiolek L, Kocot J. The many “faces” of copper in medicine and treatment. Biometals. 2014; 27(4): 611-621. https://doi.org/10.1007/s10534-014-9736-5

6. Nasulewicz A, Mazur A, Opolski A. Role of copper in tumour angiogenesis - Clinical implications. J Trace Elem Med Biol. 2004; 18(1): 1-8. https://doi.org/10.1016/j.jtemb.2004.02.004

7. Lelièvre P, Sancey L, Coll JL, Deniaud A, Busser B. The multifaceted roles of copper in cancer: A trace metal element with dysregulated metabolism, but also a target or a bullet for therapy. Cancers. 2020; 12(12): 3594. https://doi.org/10.3390/cancers12123594

8. Fang AP, Chen PY, Wang XY, Liu ZY, Zhang DM, Luo Y, et al. Serum copper and zinc levels at diagnosis and hepatocellular carcinoma survival in the Guangdong Liver Cancer Cohort. Int J Cancer. 2019; 144(11): 2823-2832. https://doi.org/10.1002/ijc.31991

9. Baldari S, Di Rocco G, Toietta G. Current biomedical use of copper chelation therapy. Int J Mol Sci. 2020; 21(3): 1069. https://doi.org/10.3390/ijms21031069

10. Frezza M, Hindo S, Chen D, Davenport A, Schmitt S, Tomco D, et al. Novel metals and metal complexes as platforms for cancer therapy. Curr Pharm Des. 2010; 16(16): 1813-1825. https://doi.org/10.2174/138161210791209009

11. Denoyer D, Masaldan S, La Fontaine S, Cater MA. Targeting copper in cancer therapy: ‘Copper That Cancer.’ Metallomics. 2015; 7(11): 1459-1476. https://doi.org/10.1039/c5mt00149h

12. Zhang Z, Wang H, Yan M, Wang H, Zhang C. Novel copper complexes as potential proteasome inhibitors for cancer treatment (Review). Mol Med Rep. 2017; 15(1): 3-11. https://doi.org/10.3892/mmr.2016.6022

13. Xia L, Tan S, Zhou Y, Lin J, Wang H, Oyang L, et al. Role of the NFκB-signaling pathway in cancer. Onco Targets Ther. 2018; 11: 2063-2073. https://doi.org/10.2147/OTT.S161109

14. Wang X, Yu T, Liao X, Yang C, Han C, Zhu G, et al. The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma. Cancer Med. 2018; 7(4): 966-980. https://doi.org/10.1002/cam4.1299

15. Ashida R, Okamura Y, Ohshima K, Kakuda Y, Uesaka K, Sugiura T, et al. CYP3A4 gene is a novel biomarker for predicting a poor prognosis in hepatocellular carcinoma. Cancer Genomics Proteomics. 2017; 14(6): 445-453. https://doi.org/10.21873/cgp.20054

16. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007; 76(3): 391-396.

17. Lu C, Di L. In vitro and in vivo methods to assess pharmacokinetic drug-drug interactions in drug discovery and development. Biopharm Drug Dispos. 2020; 41: 3-31. https://doi.org/10.1002/bdd.2212

18. Choi JM, Oh SJ, Lee SY, Im JH, Oh JM, Ryu CS, et al. HepG2 cells as an in vitro model for evaluation of cytochrome P450 induction by xenobiotics. Arch Pharm Res. 2015; 38(5): 691-704. https://doi.org/10.1007/s12272-014-0502-6

19. Kyffin JA, Sharma P, Leedale J, Colley HE, Murdoch C, Mistry P, et al. Impact of cell types and culture methods on the functionality of in vitro liver systems - A review of cell systems for hepatotoxicity assessment. Toxicol In Vitro. 2018; 48: 262-275. https://doi.org/10.1016/j.tiv.2018.01.023

20. Eremina JA, Lider EV, Sukhikh TS, Eltsov IV, Kuratieva NV, Zakharov BA, et al. Synthesis, crystal structures, spectroscopic, and cytotoxicity study of Cu(II), Co(II), Ni(II) and Pd(II) complexes with 2-anilinomethylidene-5,5-dimethylcyclohexane-1,3-dione. Polyhedron. 2020; 178. https://doi.org/10.1016/j.poly.2019.114325

21. Eremina JA, Ermakova EA, Smirnova KS, Klyushova LS, Berezin AS, Sukhikh TS, et al. Cu(II), Co(II), Mn(II) complexes with 5-phenyltetrazole and polypyridyl ligands: Synthesis, characterization and evaluation of the cytotoxicity and antimicrobial activity. Polyhedron. 2021; 206. https://doi.org/10.1016/j.poly.2021.115352

22. Eremina JA, Lider EV, Kuratieva NV, Samsonenko DG, Klyushova LS, Sheven’ DG, et al. Synthesis and crystal structures of cytotoxic mixed-ligand copper(II) complexes with alkyl tetrazole and polypyridine derivatives. Inorganica Chim Acta. 2021; 516. https://doi.org/10.1016/j.ica.2020.120169

23. Sirenko O, Mitlo T, Hesley J, Luke S, Owens W, Cromwell EF. High-content assays for characterizing the viability and morphology of 3D cancer spheroid cultures. Assay Drug Dev Technol. 2015; 13(7): 402-414. https://doi.org/10.1089/adt.2015.655

24. Mancio-Silva L, Fleming HE, Miller AB, Milstein S, Liebow A, Haslett P, et al. Improving drug discovery by nucleic acid delivery in engineered human microlivers. Cell Metab. 2019; 29(3): 727-735. e3. https://doi.org/10.1016/j.cmet.2019.02.003

25. Bibi Z. Role of cytochrome P450 in drug interactions. Nutr Metab (Lond). 2008; 5: 27. https://doi.org/10.1186/1743-7075-5-27

26. Wang X, Liao X, Yang C, Huang K, Yu T, Yu L, et al. Identification of prognostic biomarkers for patients with hepatocellular carcinoma after hepatectomy. Oncol Rep. 2019; 41(3): 1586-1602. https://doi.org/10.3892/or.2019.6953

27. Ramsden D, Tweedie DJ, Chan TS, Tracy TS. Altered CYP2C9 activity following modulation of CYP3A4 levels in human hepatocytes: an example of protein-protein interactions. Drug Metab Dispos. 2014; 42(11): 1940-1946. https://doi.org/10.1124/dmd.114.057901

28. Subramanian M, Tam H, Zheng H, Tracy TS. CYP2C9-CYP3A4 protein-protein interactions: Role of the hydrophobic N terminus. Drug Metab Dispos. 2010; 38(6): 1003-1009. https://doi.org/10.1124/dmd.109.030155

29. Dilruba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2016; 77(6): 1103-1124. https://doi.org/10.1007/s00280-016-2976-z

30. Langhans SA. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol. 2018; 9(6): 14. https://doi.org/10.3389/fphar.2018.00006